Patent Assignment
Reel/Frame 067529/0019
Assignment of Assignor's Interest
Recorded: 2024-05-24
Pages: 20
Assignor
SORRENTO THERAPEUTICS, INC.
Executed: 2024-05-10
Assignee
VIVASOR, INC.
9380 JUDICIAL DRIVE, SAN DIEGO, CALIFORNIA, 92121
Covered Properties
(50)
Antigen Binding Proteins that Bind Delta-Like 4 (DLL-4)
Antibodies Which Bind Insulin-Like Growth Factor Receptor-1 (IGF1R) and Methods of Use Thereof to Treat Cancer
Antigen Binding Proteins That Bind C-Met
Antigen Binding Proteins That Bind CCR2
Anti-Infective Binding Proteins that Bind AIP2
Drug-Conjugates, Conjugation Methods, and Uses Thereof
Drug-Conjugates, Conjugation Methods, and Uses Thereof
Anti-Infective Binding Proteins that Bind AIP2
Drug-Conjugates with a Targeting Molecule and Two Different Drugs
Fully Human Anti-C-X-C Chemokine Receptor 3 (CXCR5) Antibodies
Fully Human Anti-CXC Chemokine Receptor 5 (CXCR5) Antibodies
Antibody Drug Conjugates
Antibody Therapeutics That Bind CTLA4
Antibody Therapeutics That Bind CD38
Antibody Therapeutics That Bind CD38
Antigen Binding Proteins that Bind CCR2
Anti-Infective Binding Proteins That Bind AIP2
Antibody Drug Conjugates Having Derivatives of Amatoxin as the Drug
Methods for Treating Subjects Having a Cxc Chemokine Receptor 5 (CXCR5)-Responsive Cancer by Administering Fully Human Anti-CXCR5 Antibodies
Drug-Conjugates, Conjugation Methods, and Uses Thereof
Antigen Binding Proteins that Bind CCR2
CD38 Antibody Drug Conjugate
Antibody Therapeutics That Bind CD38
Fully Human Anti-C-X-C Chemokine Receptor 3 (CXCR3) Antibodies and Methods of Use Thereof
CD-38 Directed Chimeric Antigen Receptor Constructs
Variant Antibodies That Bind AIP2
Methods for Blocking an Interaction Between Notch-1 and Delta-Like 4 (Dll-4) by Administering a Ddl-4 Antibody
Antibody Therapeutics That Bind CTLA4
Antigen Binding Proteins That Bind C-Met
Drug-Conjugates, Conjugation Methods, and Uses Thereof
Application:
16/886,535 →
Dimeric Antigen Receptors
Antibody Therapeutics that Bind CD38
Drug-Conjugates With a Targeting Molecule and Two Different Drugs
Variant Antibody That Binds Cd38
Application:
17/127,766 →
Publication:
US 2021/0130484
Drug-Conjugates, Conjugation Methods, And Uses Thereof
Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug
Application:
17/240,700 →
Publication:
US 2021/0260211
Antigen Binding Proteins that Bind BCMA
Application:
17/412,089 →
Publication:
US 2021/0388097
Antibody Therapeutics that Bind CTLA4
Application:
17/482,138 →
Publication:
US 2022/0002415
Antigen Binding Proteins that Bind c-Met
Application:
17/482,140 →
Publication:
US 2022/0002422
CD38 Antibody Drug Conjugate
Application:
17/518,375 →
Publication:
US 2022/0118105
Engineered Variant Antibodies that Bind CD38
Application:
17/599,377 →
Publication:
US 2022/0144966
Cannabidiol Pharmaceutical Compositions
Application:
17/601,357 →
Publication:
US 2022/0183999
Dimeric Antigen Receptors (DAR) that Bind BCMA
Application:
17/686,261 →
Publication:
US 2022/0251168
Dimeric Antigen Receptors (DAR) That Bind CD20
Application:
17/820,165 →
Publication:
US 2023/0061838
Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
Application:
17/908,814 →
Publication:
US 2023/0096410
Oncolytic Herpes Simplex Viruses (Hsv) Expressing Immunomodulatory Fusion Proteins
Application:
18/002,336 →
Publication:
US 2023/0357793
CD19-Directed Chimeric Antigen Receptor Constructs
Application:
18/248,079 →
Publication:
US 2024/0261330
Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
Application:
18/279,768 →
Publication:
US 2024/0181073
Dimeric Antigen Receptors (DARs) that Bind GD2
Application:
18/287,255 →
Publication:
US 2024/0197881
Oncolytic Viruses Expressing Anti-ROR1/Anti-CD3 Bispecific Antibodies
Application:
18/482,391 →
Related Assignments
(7)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 13, 2018
From: GRAY, JOHN DIXON; ZHOU, HEYUE
To: SORRENTO THERAPEUTICS, INC.
Reel/Frame 045192/0842 →
Security Interest
Nov 7, 2018
From: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 047446/0335 →
Release of Security Interest
Jul 31, 2020
From: OAKTREE FUND ADMINISTRATION, LLC
To: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.
Reel/Frame 053368/0577 →
Security Interest
Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
Security Interest
Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
Release of Security Interest
Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
Termination and Release of Security Interest in Intellectual Property
Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →